DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Tannir NM, Frontera OA, Hammers HJ. et al.
Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
Journal of Clinical Oncology 2019;
37: 547-547
Access:
We do not assume any responsibility for the contents of the web pages of other providers.